Difference between revisions of "Team:UCSC/Project"
Evan pepper (Talk | contribs) |
Evan pepper (Talk | contribs) |
||
| (47 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
<style> | <style> | ||
| − | . | + | .metabolic-pathway { |
| − | margin | + | margin: auto; |
| − | + | ||
| − | + | ||
background: honeydew; | background: honeydew; | ||
| + | width: 100%; | ||
} | } | ||
| Line 14: | Line 13: | ||
font-size: 300%; /*!important*/ | font-size: 300%; /*!important*/ | ||
font-weight: 300 !important; | font-weight: 300 !important; | ||
| − | width: | + | width: 90%; |
} | } | ||
| Line 21: | Line 20: | ||
font-size: 200%; | font-size: 200%; | ||
font-weight: 300; | font-weight: 300; | ||
| + | } | ||
| + | |||
| + | h3 { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 120%; | ||
| + | font-weight: 200; | ||
} | } | ||
| Line 29: | Line 34: | ||
.proj-button { | .proj-button { | ||
position: relative; | position: relative; | ||
| − | width: | + | width: 25%; |
| + | text-decoration: none !important; | ||
} | } | ||
| Line 35: | Line 41: | ||
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 19%; |
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| + | |||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 65%; | ||
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
| Line 50: | Line 65: | ||
transform: translate(-50%, -50%); | transform: translate(-50%, -50%); | ||
-ms-transform: translate(-50%, -50%) | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: transparent; | ||
| + | color: black; | ||
| + | font-size: 20px; | ||
| + | font-family: "Objektiv-mk1" !important; | ||
| + | font-weight: 400 !important; | ||
| + | padding: 16px 32px; | ||
} | } | ||
.proj-button:hover .proj-button-image { | .proj-button:hover .proj-button-image { | ||
| + | opacity: 0.3; | ||
| + | } | ||
| + | |||
| + | .proj-button:hover .proj-button-image-solo { | ||
opacity: 0.3; | opacity: 0.3; | ||
} | } | ||
| Line 60: | Line 88: | ||
} | } | ||
| − | . | + | .text { |
background-color: transparent; | background-color: transparent; | ||
color: black; | color: black; | ||
font-size: 20px; | font-size: 20px; | ||
| − | |||
| − | |||
padding: 16px 32px; | padding: 16px 32px; | ||
} | } | ||
| − | . | + | .paragraph-left { |
font-family: 'objektiv-mk1' !important; | font-family: 'objektiv-mk1' !important; | ||
| − | + | font-size: 18px; | |
| + | text-align: left; | ||
| + | vertical-align: middle; | ||
} | } | ||
p { | p { | ||
font-family: 'objektiv-mk1' !important; | font-family: 'objektiv-mk1' !important; | ||
| + | /* margin-left: 200px !important; | ||
| + | margin-right: 200px !important;*/ | ||
font-size: large !important; | font-size: large !important; | ||
} | } | ||
| Line 81: | Line 111: | ||
.firstword { | .firstword { | ||
font-family: 'objektiv-mk1' !important; | font-family: 'objektiv-mk1' !important; | ||
| − | font-size: | + | font-size: 65px; |
| + | } | ||
| + | .quote { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-style: italic !important; | ||
| + | font-size: 28px; | ||
| + | line-height: 130%; | ||
| + | } | ||
| + | |||
| + | .quote-person { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 22px; | ||
| + | width: 100% !important; | ||
| + | text-align: right !important; | ||
| + | padding-right: 80px !important; | ||
} | } | ||
.titleimg { | .titleimg { | ||
vertical-align: middle; | vertical-align: middle; | ||
| − | width: | + | width: 15%; |
} | } | ||
.titlebox { | .titlebox { | ||
| − | margin-left: | + | margin-left: 0px !important; |
} | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | } | ||
| + | |||
| + | .reference-italic { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | font-style: italic; | ||
| + | } | ||
| + | |||
| + | figcaption { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-style: italic; | ||
| + | font-size: 13px; | ||
| + | } | ||
| + | |||
@media (min-width: 1144px) { | @media (min-width: 1144px) { | ||
.container { | .container { | ||
| − | + | width: 80% !important; | |
| − | + | } | |
| + | |||
.text-container { | .text-container { | ||
width: 60%; | width: 60%; | ||
| − | padding-left: | + | padding-left: 30px; |
| − | padding-right: | + | padding-right: 30px; |
} | } | ||
| + | |||
.titlebox { | .titlebox { | ||
width: 80%; | width: 80%; | ||
} | } | ||
| + | |||
figcaption { | figcaption { | ||
font-size: 16px; | font-size: 16px; | ||
| Line 115: | Line 184: | ||
margin-left: auto !important; | margin-left: auto !important; | ||
} | } | ||
| + | |||
| + | p { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | margin-left: 10px !important; | ||
| + | margin-right: 10px !important; | ||
| + | font-size: medium !important; | ||
| + | } | ||
| + | |||
| + | .quote { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-style: italic !important; | ||
| + | font-size: 26px; | ||
| + | } | ||
| + | |||
| + | .quote-person { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 20px; | ||
| + | width: 100%; | ||
| + | text-align: right; | ||
| + | padding-right: 80px !important; | ||
| + | } | ||
| + | |||
| + | .metabolic-pathway { | ||
| + | margin: auto; | ||
| + | background: honeydew; | ||
| + | width: 100%; | ||
| + | } | ||
| + | |||
| + | .container { | ||
| + | width: 70% !important; | ||
| + | padding-left: 0px !important; | ||
| + | padding-right: 0px !important; | ||
| + | } | ||
.text-container { | .text-container { | ||
width: 80%; | width: 80%; | ||
| − | padding-left: | + | padding-left: 0px; |
| − | padding-right: | + | padding-right: 0px; |
} | } | ||
| − | + | figcaption { | |
| − | + | font-size: 14px; | |
| − | + | ||
| − | + | ||
| − | font-size: | + | |
} | } | ||
| + | } | ||
| + | |||
| + | @media (max-width: 992px) { | ||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 30%; | ||
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
} | } | ||
| Line 134: | Line 244: | ||
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 32%; |
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| + | |||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 35%; | ||
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
| Line 142: | Line 261: | ||
.proj-button-desc { | .proj-button-desc { | ||
transition: .5s ease; | transition: .5s ease; | ||
| − | opacity: | + | opacity: 0; |
position: absolute; | position: absolute; | ||
top: 100%; | top: 100%; | ||
| Line 148: | Line 267: | ||
transform: translate(-50%, -50%); | transform: translate(-50%, -50%); | ||
-ms-transform: translate(-50%, -50%) | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: rgba(94, 94, 94, 0.0); | ||
| + | border-radius: 60px; | ||
| + | color: white; | ||
} | } | ||
h1 { | h1 { | ||
font-family: 'objektiv-mk1'; /*!important*/ | font-family: 'objektiv-mk1'; /*!important*/ | ||
| − | font-size: | + | font-size: 220%; /*!important*/ |
| + | width: 80%; | ||
} | } | ||
| − | + | h2 { | |
font-family: 'objektiv-mk1'; /*!important*/ | font-family: 'objektiv-mk1'; /*!important*/ | ||
font-size: 20px; /*!important*/ | font-size: 20px; /*!important*/ | ||
| + | } | ||
| + | |||
| + | .quote { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-style: italic !important; | ||
| + | font-size: 20px; | ||
| + | } | ||
| + | |||
| + | .quote-person { | ||
| + | width: 100%; | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 16px; | ||
| + | text-align: right !important; | ||
| + | padding-right: 20px !important; | ||
} | } | ||
.text-container { | .text-container { | ||
| − | width: | + | width: 82%; |
| + | padding-left: 0px; | ||
| + | padding-right: 0px; | ||
} | } | ||
| + | figcaption { | ||
| + | font-size: 14px; | ||
| + | line-height: 140%; | ||
| + | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | margin-right: -70px; | ||
| + | margin-left: -70px; | ||
| + | } | ||
| + | } | ||
/* p { | /* p { | ||
margin-left: 10px !important; | margin-left: 10px !important; | ||
| Line 174: | Line 332: | ||
opacity: 1; | opacity: 1; | ||
display: inline-block; | display: inline-block; | ||
| − | width: | + | width: 50%; |
| + | height: auto; | ||
| + | transition: .5s ease; | ||
| + | backface-visibility: hidden; | ||
| + | } | ||
| + | |||
| + | .proj-button-image-solo { | ||
| + | opacity: 1; | ||
| + | display: inline-block; | ||
| + | width: 50%; | ||
height: auto; | height: auto; | ||
transition: .5s ease; | transition: .5s ease; | ||
| Line 182: | Line 349: | ||
.proj-button-desc { | .proj-button-desc { | ||
transition: .5s ease; | transition: .5s ease; | ||
| − | opacity: | + | opacity: 0; |
position: absolute; | position: absolute; | ||
top: 100%; | top: 100%; | ||
| Line 188: | Line 355: | ||
transform: translate(-50%, -50%); | transform: translate(-50%, -50%); | ||
-ms-transform: translate(-50%, -50%) | -ms-transform: translate(-50%, -50%) | ||
| + | } | ||
| + | |||
| + | .overlap-button-text { | ||
| + | background-color: rgba(94, 94, 94, 0.0); | ||
| + | border-radius: 60px; | ||
| + | color: white; | ||
| + | font-size: 12px; | ||
} | } | ||
.firstword { | .firstword { | ||
font-family: 'objektiv-mk1' !important; | font-family: 'objektiv-mk1' !important; | ||
| − | font-size: | + | font-size: 40px; |
} | } | ||
.titleimg { | .titleimg { | ||
vertical-align: middle; | vertical-align: middle; | ||
| − | width: | + | width: 40%; |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
} | } | ||
| Line 211: | Line 379: | ||
margin-right: 10px !important; | margin-right: 10px !important; | ||
font-size: small !important; | font-size: small !important; | ||
| + | } | ||
| + | |||
| + | h1 { | ||
| + | font-size: 160%; | ||
| + | } | ||
| + | |||
| + | .quote { | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-style: italic !important; | ||
| + | font-size: 17px; | ||
| + | } | ||
| + | |||
| + | .quote-person { | ||
| + | width: 60% !important; | ||
| + | font-family: 'objektiv-mk1' !important; | ||
| + | font-size: 12px; | ||
| + | text-align: right !important; | ||
| + | margin-right: -120px !important; | ||
| + | } | ||
| + | |||
| + | .paragraph-left { | ||
| + | font-size: 13px; | ||
| + | line-height: 170%; | ||
| + | } | ||
| + | |||
| + | .text-container { | ||
| + | width: 85%; | ||
| + | padding-left: 0px; | ||
| + | padding-right: 0px; | ||
| + | } | ||
| + | |||
| + | .metabolic-pathway { | ||
| + | margin: auto; | ||
| + | background: honeydew; | ||
| + | width: 110%; | ||
| + | margin-left: -20px; | ||
| + | margin-right: -20px; | ||
| + | } | ||
| + | |||
| + | figcaption { | ||
| + | font-size: 12px; | ||
| + | line-height: 130%; | ||
| + | } | ||
| + | |||
| + | .reference-list { | ||
| + | font-family: 'objektiv-mk1'; | ||
| + | font-size: 12px; | ||
| + | text-align: left; | ||
| + | list-style-type: none; | ||
| + | line-height: 100%; | ||
| + | margin-bottom: 80px; | ||
| + | margin-right: -50px; | ||
| + | margin-left: -50px; | ||
| + | } | ||
| + | } | ||
| + | |||
| + | @media (max-width: 400px) { | ||
| + | .quote { | ||
| + | font-size: 15px; | ||
} | } | ||
} | } | ||
| Line 235: | Line 462: | ||
</div>--> | </div>--> | ||
| + | <center><img class='titleimg' src="https://static.igem.org/mediawiki/2017/3/36/Projectimg.png"></center> | ||
<h1>PROJECT DESCRIPTION</h1><br> | <h1>PROJECT DESCRIPTION</h1><br> | ||
| Line 247: | Line 475: | ||
<div class="text-container"> | <div class="text-container"> | ||
| − | <p><span class="firstword"> | + | <p><span class="firstword">Malnutrition</span> and inconsistent access to medicine are widespread global problems. While a great deal of progress has been made, micronutrient deficiency remains one of the leading causes of global disease burden, especially in non-industrialized regions<sup>[1]</sup>. Our project, <i>Bugs Without Borders</i>, aims to decentralize production of medical and dietary supplements by engineering the alkali photoautotroph, <i>Arthrospira platensis</i>, commonly referred to as Spirulina. <i>A. platensis</i> is the most quintessential organism for growth at “on-site” healthcare facilities due to its modest media cost, alkali growth conditions, and its inherent properties as a nutritional “superfood"<sup>[2]</sup>.</p> |
| − | + | <br> | |
| + | <br> | ||
| − | <p> | + | <center> |
| − | + | <img class="metabolic-pathway" src="https://static.igem.org/mediawiki/2017/5/59/Cyanobuddies.png"> | |
| + | </center> | ||
| + | |||
| + | <br> | ||
| + | <br> | ||
| + | |||
| + | <p>Based on information we gathered through correspondence with international healthcare professionals, acetaminophen and vitamin DMB B<sub>12</sub> (the form of vitamin B<sub>12</sub> that mammals can absorb) were selected from the World Health Organization (WHO)’s published Essential Medicines List as the most impactful products our photosynthetic “factories” could manufacture<sup>[3]</sup>.</p> | ||
| + | |||
| + | <br> | ||
| + | |||
| + | <p>The integration and performance of the genes in acetaminophen production, <i>4ABH</i> and <i>nhoA</i>, and those in vitamin DMB B<sub>12</sub> production, <i>ssuE</i> and <i>bluB</i>, were investigated in the model cyanobacteria, <i>Synechococcus elongatus</i> PCC 7942 with the aim of subsequent integration into <i>A. platensis</i> once a genetic system has been studied and established. An <i>in vivo</i> vitamin B<sub>12</sub> detection system was also optimized for <i>S. elongatus</i> and <i>E. coli</i> by altering the ribosome binding site on the B<sub>12</sub> riboswitch (part BBa_K1913011) and the <i>psbAI</i> (part BBa_K754000) promoter we used for its transcription. In addition, we aim to sequence the entire genome of <i>A. platensis</i> UTEX 2340 to further enable genetic research in this organism and its potential medical applications.</p> | ||
| + | |||
| + | </div> | ||
| − | |||
| − | |||
<br> | <br> | ||
<br> | <br> | ||
| Line 263: | Line 502: | ||
<div class="row"> | <div class="row"> | ||
<a href="https://2017.igem.org/Team:UCSC/Acetaminophen" class="proj-button"> | <a href="https://2017.igem.org/Team:UCSC/Acetaminophen" class="proj-button"> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/6/6c/Acetaminophenicon.png" class="proj-button-image"> |
<div class="proj-button-desc"> | <div class="proj-button-desc"> | ||
| − | <div class="overlap-button-text"> | + | <div class="overlap-button-text">ACETAMINOPHEN</div> |
</div> | </div> | ||
</a> | </a> | ||
<a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button"> | <a href="https://2017.igem.org/Team:UCSC/B-12" class="proj-button"> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/a/a2/B12_flask_button.png" class="proj-button-image"> |
<div class="proj-button-desc"> | <div class="proj-button-desc"> | ||
| − | <div class="overlap-button-text"> | + | <div class="overlap-button-text">VITAMIN B<sub>12</sub></div> |
</div> | </div> | ||
</a> | </a> | ||
<a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button"> | <a href="https://2017.igem.org/Team:UCSC/Model" class="proj-button"> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/b/be/Modeling_button.png" class="proj-button-image"> |
<div class="proj-button-desc"> | <div class="proj-button-desc"> | ||
| − | <div class="overlap-button-text"> | + | <div class="overlap-button-text">MODELING</div> |
</div> | </div> | ||
</a> | </a> | ||
| + | </div> | ||
| + | <div class="row"> | ||
| − | <a href="https://2017.igem.org/Team:UCSC/ | + | <a href="https://2017.igem.org/Team:UCSC/Demonstrate" class="proj-button"> |
| − | <img src="https://static.igem.org/mediawiki/2017/ | + | <img src="https://static.igem.org/mediawiki/2017/a/ad/Resulticon.png" class="proj-button-image"> |
<div class="proj-button-desc"> | <div class="proj-button-desc"> | ||
| − | <div class="overlap-button-text"> | + | <div class="overlap-button-text">RESULTS</div> |
</div> | </div> | ||
</a> | </a> | ||
| − | <a href="https://2017.igem.org/Team:UCSC/ | + | <a href="https://2017.igem.org/Team:UCSC/Target-Organism" class="proj-button"> |
| + | <img src="https://static.igem.org/mediawiki/2017/8/84/Spirulinaicon.png" class="proj-button-image"> | ||
| + | <div class="proj-button-desc"> | ||
| + | <div class="overlap-button-text">TARGET ORGANISM</div> | ||
| + | </div> | ||
| + | </a> | ||
| + | |||
| + | <a href="https://2017.igem.org/Team:UCSC/Part_Collection" class="proj-button"> | ||
<img src="https://static.igem.org/mediawiki/2017/9/9c/Parts_icon.png" class="proj-button-image"> | <img src="https://static.igem.org/mediawiki/2017/9/9c/Parts_icon.png" class="proj-button-image"> | ||
<div class="proj-button-desc"> | <div class="proj-button-desc"> | ||
| − | <div class="overlap-button-text"> | + | <div class="overlap-button-text">PARTS</div> |
</div> | </div> | ||
</a> | </a> | ||
| + | |||
| + | <br> | ||
| + | <br> | ||
| + | |||
| + | <div class="container"> | ||
| + | <div class="container"> | ||
| + | <div class="reference-list"> | ||
| + | <hr> | ||
| + | <li>[1] Taylor, D. W., & CIM, F. (2010). Pharmaceutical Access in Least Developed Countries: on-the-ground barriers and industry successes”. Cameron Institute, October.</li> | ||
| + | <li>[2] Spirulina Benefits: 7 Reasons to Try It (& 1 Major Caution) Wellness Mama. (n.d.). Retrieved October 26, 2017, from https://wellnessmama.com/4738/spirulina-benefits/</li> | ||
| + | <li>[3] World Health Organization, ed., <i>The Selection and Use of Essential Medicines: report of the WHO Expert Committee, 2007; (including the 15th model list of essential medicines</i>). No. 946in WHO Technical Report Series, Geneva: World Health Organization, 2007. OCLC: 254437808.</li> | ||
| + | </div> | ||
| + | </div> | ||
| + | </div> | ||
| + | |||
| + | <br> | ||
| + | <br> | ||
</div> | </div> | ||
Latest revision as of 02:47, 2 November 2017
PROJECT DESCRIPTION
Malnutrition and inconsistent access to medicine are widespread global problems. While a great deal of progress has been made, micronutrient deficiency remains one of the leading causes of global disease burden, especially in non-industrialized regions[1]. Our project, Bugs Without Borders, aims to decentralize production of medical and dietary supplements by engineering the alkali photoautotroph, Arthrospira platensis, commonly referred to as Spirulina. A. platensis is the most quintessential organism for growth at “on-site” healthcare facilities due to its modest media cost, alkali growth conditions, and its inherent properties as a nutritional “superfood"[2].
Based on information we gathered through correspondence with international healthcare professionals, acetaminophen and vitamin DMB B12 (the form of vitamin B12 that mammals can absorb) were selected from the World Health Organization (WHO)’s published Essential Medicines List as the most impactful products our photosynthetic “factories” could manufacture[3].
The integration and performance of the genes in acetaminophen production, 4ABH and nhoA, and those in vitamin DMB B12 production, ssuE and bluB, were investigated in the model cyanobacteria, Synechococcus elongatus PCC 7942 with the aim of subsequent integration into A. platensis once a genetic system has been studied and established. An in vivo vitamin B12 detection system was also optimized for S. elongatus and E. coli by altering the ribosome binding site on the B12 riboswitch (part BBa_K1913011) and the psbAI (part BBa_K754000) promoter we used for its transcription. In addition, we aim to sequence the entire genome of A. platensis UTEX 2340 to further enable genetic research in this organism and its potential medical applications.
Click on an icon below to learn more about our project!
